Mackenzie Financial
CRSP icon

Mackenzie Financial’s CRISPR Therapeutics CRSP Stock Holding History

Mackenzie Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,187
Closed -$275K – 1496
2025
Q4 		$275K Sell
5,187
-235
-4% -$14.1K ﹤0.01% 1414
2025
Q3 		$351K Buy
+5,422
New +$311K ﹤0.01% 1354
2022
Q1 		– Sell
-24,300
Closed -$1.84M – 1429
2021
Q4 		$1.84M Buy
+24,300
New +$2.12M ﹤0.01% 781

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Mackenzie Financial's CRSP Position: Q1 2026 in Review

Mackenzie Financial sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 5,187 shares — an estimated $275K sold.

Mackenzie Financial first reported a position in CRSP in Q4 2021 and held it in 3 quarters. The position peaked at $1.84M in Q4 2021. 491 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Mackenzie Financial reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 5,187 CRISPR Therapeutics shares in Q1 2026, an estimated $275K.
  • Mackenzie Financial first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 3 quarters.
  • Mackenzie Financial's CRISPR Therapeutics position peaked at $1.84M in Q4 2021.
  • 491 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.